A Phase 2 interventional study of Avapritinib in Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis and Systemic Mastocytosis With an Associated Hematologic Neoplasm, sponsored by Blueprint Medicines Corporation. Completed at 32 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Leukemia, Mast-Cell with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Mast-Cell · United States.
Among the 48 studies in Leukemia, Mast-Cell with a site in United States, this one is the 9th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 42nd registered.
60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.
Browse Leukemia, Mast-Cell studies →4 of the 48 studies in Leukemia, Mast-Cell with a site in United States are open now. Recruiting first, the newest first:
Cogent Biosciences, Inc. · Sites in United States, Australia, Austria and 11 more countries
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 65+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18–120
Fred Hutchinson Cancer Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Leukemia, Mast-Cell studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 4
First in 1991; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 50 across 38 interventional studies indexed under Leukemia, Mast-Cell.
Median enrollment 45 across the 34 interventional studies, 530 across the 12 observational. Of the 40 that completed or were terminated, 17 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blueprint Medicines Corporation, one of the names counted as Sanofi. Under that name alone:
Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.
Sanofi has 5 studies filed under Leukemia, Mast-Cell — fewer than ten, so there is no comparison to draw.
1 of the studies in Leukemia, Mast-Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03779854Fred Hutchinson Cancer CenterNaive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies in Leukemia, Mast-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.
This study's enrollment of 107 is above the median of 50 across 38 interventional studies indexed under Leukemia, Mast-Cell.
Browse Leukemia, Mast-Cell studies →Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.
First submitted before Blueprint Medicines Corporation became part of Sanofi.
Compared within Leukemia, Mast-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mastocytosis, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
Drug: Avapritinib
Avapritinib tablet
Also known as: BLU-285
Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria
ORR was defined as the percentage of participants with a confirmed best response of complete remission (CR), complete remission with partial recovery of peripheral blood counts (CRh), partial remission (PR), or clinical improvement (CI) by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.
Time frame: Baseline through Month 65
Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)
The AdvSM-SAF is a 10-item questionnaire that assesses eight symptoms specific to AdvSM. All eight symptoms are scored on a scale of 0 (absence of symptoms) to 10 (more severe symptoms) (up to 80 points maximum). Each symptom contributes to the TSS equally. The TSS was generated based on average scores for each 7-day period. An increase in score from 0 (no symptoms) to 80 (worst symptoms represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an electronic diary (eDiary). Each cycle is 28 days long.
Time frame: Baseline up to Month 6 (Cycle 6, Day 1)
ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator
ORR was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, or CI by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.
Time frame: Baseline through Month 19
Time-to-Response (TTR)
TTR was defined as the time from first dose to the time of initial evaluation of clinical improvement (CI) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
Time frame: Baseline through Month 65
Duration of Response (DOR)
DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
Time frame: Baseline through Month 65
Progression-free Survival (PFS)
PFS was defined as time from first dose to the time of initial documentation of confirmed PD or death due to any cause, whichever occurred first. Participants who had not progressed or died at the time of analysis were censored at the last response assessment that was SD or better.
Time frame: Baseline through Month 65
Overall Survival (OS)
OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.
Time frame: Baseline through Month 65
Objective Response Rate
The objective response rate was defined as the number of participants with a confirmed best response of morphologic complete remission, morphologic complete remission with partial recovery of peripheral blood counts, or morphologic partial remission by pure pathologic response (PPR) criteria. The PPR criteria are a modification of the mIWG-MRT-ECNM criteria that define deep responses where direct measure of the disease burden determined the response and focus on objective changes (bone marrow mast cell burden, serum tryptase, and complete blood count).
Time frame: Baseline through Month 65
Clinical Benefit Rate
The clinical benefit rate was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, CI, and SD by mIWG-MRT-ECNM criteria.
Time frame: Baseline through Month 65
Percent Change From Baseline in Bone Marrow Mast Cells
Bone marrow biopsies and aspirates and peripheral blood smears were obtained for systemic mastocytosis response assessment according to mIWG-MRT-ECNM criteria. Each cycle is 28 days long.
Time frame: Baseline up to Month 65
Percent Change From Baseline in Serum Tryptase
Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.
Time frame: Baseline up to Month 65
Percent Change From Baseline in V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Aspartate 816 Valine (KIT D816V) Mutation Burden
Bone marrow aspirate and PB samples were collected to characterize the KIT D816V mutation allele fraction. Each cycle is 28 days long.
Time frame: Baseline up to Month 65
Percent Change From Baseline in Liver Volume by Imaging
Assessment of liver volume was performed using serial imaging with magnetic resonance imaging (MRI). Response was defined as resolution of palpable hepatomegaly (CR). Each cycle is 28 days long.
Time frame: Baseline up to Month 65
Percent Change From Baseline in Spleen Volume by Imaging
Assessment of spleen volume was performed using serial imaging with MRI. Response was defined as ≥35% reduction in spleen volume (PR) or resolution of palpable splenomegaly (CR). Each cycle is 28 days long.
Time frame: Baseline up to Month 65
Mean Change From Baseline in AdvSM-SAF Skin and Gastrointestinal Domain Scores at Month 10
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Eight symptoms are scored on a scale of 0 to 10 for severity and 2 symptoms (vomiting and diarrhea) are scored for number of episodes. The skin domain is scored on a scale of 0-30, where 0 represents an absence of symptoms and 30 the most severe symptom experience. Similarly, the gastrointestinal domain is scored on a scale of 0-40, where 0 represents an absence of symptoms and 40 the most severe symptom experience. Skin and gastrointestinal domain scores were generated based on average scores for each 7-day period. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
Time frame: Baseline, Month 10
Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Severity) at Month 10
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Eight symptoms are scored on a scale of 0 to 10 for severity. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
Time frame: Baseline, Month 10
Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Episodes) at Month 10
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Two symptoms (vomiting and diarrhea) are scored for number of episodes. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
Time frame: Baseline, Month 10
Change From Baseline in Patient's Global Impression of Symptom Severity (PGIS)
The PGIS is a single-item scale that assesses a participant's perception of disease symptoms at a point in time. Scores range from 0 to 4 points, with higher values representing worse symptom outcomes. It is widely used to evaluate a participant's overall sense of whether a treatment has been beneficial. Each cycle is 28 days long.
Time frame: Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Quality of life was assessed using EORTC QLQ-C30, which is a 30-item questionnaire that includes 5 functional domains (physical, cognitive, role, emotional, and social) and a global health status scale. Twenty-eight questions are scored from 1 (not at all) to 4 (very much), while the other 2 are scored from 1 (very poor) to 7 (excellent). The calculated average is standardized using a linear transformation to a standardized scale of 0 to 100, with a decrease in score representing a decrease in quality of life. Each cycle is 28 days long.
Time frame: Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)
A TEAE was defined as any adverse events that occurred between the first dose of a study drug through 30 days after the last dose of any study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline through Month 65
Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib
Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).
Time frame: Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)
Correlation Between TSS and Serum Tryptase
The change in baseline for AdvSM-SAF TSS was correlated with the change in baseline for serum tryptase. Spearman correlation coefficients were performed with corresponding scatter plots on change from baseline.
Time frame: Baseline, Month 10
The Avapritinib group (N=107) includes all participants treated at a starting dose of 200 milligrams (mg) once daily (N=105) and 2 participants treated at a starting dose of 100 mg once daily. One participant was treated at a starting dose of 100 mg per previous protocol amendment, and 1 participant was treated at a starting dose of 100 mg per principal investigator decision.
| Milestone | Avapritinib (100 mg) | Avapritinib (200 mg) |
|---|---|---|
| Started | 2 | 105 |
| Received at least 1 dose of study drug | 2 | 105 |
| Pure pathologic response-evaluable population | 2 | 105 |
| Response-evaluable population | 2 | 81 |
| Completed | 0 | 0 |
| Not completed | 2 | 105 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Participant non-compliance | 0 | 2 |
| Withdrew: Physician decision | 0 | 5 |
| Withdrew: Intracranial hemorrhage | 0 | 1 |
| Withdrew: Sponsor decision | 1 | 43 |
| Withdrew: Withdrawal by subject | 0 | 19 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 1 | 33 |
ORR was defined as the percentage of participants with a confirmed best response of complete remission (CR), complete remission with partial recovery of peripheral blood counts (CRh), partial remission (PR), or clinical improvement (CI) by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.
| Percentage of Participants | Avapritinib |
|---|---|
| Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria | 73.5 (62.7 to 82.6) |
The AdvSM-SAF is a 10-item questionnaire that assesses eight symptoms specific to AdvSM. All eight symptoms are scored on a scale of 0 (absence of symptoms) to 10 (more severe symptoms) (up to 80 points maximum). Each symptom contributes to the TSS equally. The TSS was generated based on average scores for each 7-day period. An increase in score from 0 (no symptoms) to 80 (worst symptoms represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an electronic diary (eDiary). Each cycle is 28 days long.
| Score on a Scale | Avapritinib |
|---|---|
| Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS) | -6.40 ± 9.158 |
ORR was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, or CI by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.
| Percentage of Participants | Avapritinib |
|---|---|
| ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator | 53.1 (34.7 to 70.9) |
TTR was defined as the time from first dose to the time of initial evaluation of clinical improvement (CI) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
| Months | Avapritinib |
|---|---|
| Time-to-Response (TTR) | 2.30 (0.3 to 20.3) |
DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
| Months | Avapritinib |
|---|---|
| Duration of Response (DOR) | 57.8 (46.1 to NA) |
PFS was defined as time from first dose to the time of initial documentation of confirmed PD or death due to any cause, whichever occurred first. Participants who had not progressed or died at the time of analysis were censored at the last response assessment that was SD or better.
| Months | Avapritinib |
|---|---|
| Progression-free Survival (PFS) | 51.3 (38.7 to NA) |
OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.
| Months | Avapritinib |
|---|---|
| Overall Survival (OS) | 61.6 (60.0 to NA) |
The objective response rate was defined as the number of participants with a confirmed best response of morphologic complete remission, morphologic complete remission with partial recovery of peripheral blood counts, or morphologic partial remission by pure pathologic response (PPR) criteria. The PPR criteria are a modification of the mIWG-MRT-ECNM criteria that define deep responses where direct measure of the disease burden determined the response and focus on objective changes (bone marrow mast cell burden, serum tryptase, and complete blood count).
| Percentage of Participants | Avapritinib |
|---|---|
| Objective Response Rate | 73.8 (64.4 to 81.9) |
The clinical benefit rate was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, CI, and SD by mIWG-MRT-ECNM criteria.
| Percentage of Participants | Avapritinib |
|---|---|
| Clinical Benefit Rate | 89.2 (80.4 to 94.9) |
Bone marrow biopsies and aspirates and peripheral blood smears were obtained for systemic mastocytosis response assessment according to mIWG-MRT-ECNM criteria. Each cycle is 28 days long.
| Percent Change | Avapritinib |
|---|---|
| Cycle 3, Day 1 | -63.74 ± 39.445 |
| Cycle 7, Day 1 | -71.12 ± 35.602 |
| Cycle 11, Day 1 | -73.10 ± 49.885 |
| Cycle 17, Day 1 | -81.33 ± 32.377 |
| Cycle 23, Day 1 | -80.84 ± 29.283 |
| Cycle 29, Day 1 | -78.90 ± 29.181 |
| Cycle 35, Day 1 | -83.53 ± 28.316 |
| Cycle 41, Day 1 | -83.32 ± 21.374 |
| Cycle 47, Day 1 | -81.38 ± 21.656 |
| Cycle 53, Day 1 | -75.83 ± 29.094 |
| Cycle 59, Day 1 | -79.55 ± 21.921 |
| Cycle 65, Day 1 | -68.03 ± 26.781 |
Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.
| Percent Change | Avapritinib |
|---|---|
| Cycle 1, Day 15 | -64.54 ± 41.191 |
| Cycle 2, Day 1 | -68.54 ± 42.091 |
| Cycle 3, Day 1 | -71.76 ± 40.023 |
| Cycle 7, Day 1 | -75.18 ± 45.822 |
| Cycle 11, Day 1 | -78.69 ± 36.038 |
| Cycle 17, Day 1 | -85.22 ± 26.070 |
| Cycle 23, Day 1 | -85.61 ± 30.510 |
| Cycle 29, Day 1 | -83.50 ± 40.716 |
| Cycle 35, Day 1 | -83.39 ± 45.603 |
| Cycle 41, Day 1 | -90.64 ± 14.206 |
| Cycle 47, Day 1 | -90.64 ± 12.581 |
| Cycle 53, Day 1 | -68.65 ± 85.482 |
| Cycle 59, Day 1 | -92.23 ± 6.8211 |
| Cycle 65, Day 1 | -82.01 ± 14.529 |
Bone marrow aspirate and PB samples were collected to characterize the KIT D816V mutation allele fraction. Each cycle is 28 days long.
| Percent Change | Avapritinib |
|---|---|
| Cycle 1, Day 15 | -14.65 ± 21.049 |
| Cycle 2, Day 1 | -41.68 ± 23.171 |
| Cycle 3, Day 1 | -54.32 ± 31.272 |
| Cycle 7, Day 1 | -65.46 ± 32.953 |
| Cycle 11, Day 1 | -67.77 ± 30.802 |
| Cycle 17, Day 1 | -77.25 ± 26.783 |
| Cycle 23, Day 1 | -77.09 ± 29.838 |
| Cycle 29, Day 1 | -80.97 ± 29.775 |
| Cycle 35, Day 1 | -81.93 ± 31.110 |
| Cycle 41, Day 1 | -85.31 ± 24.911 |
| Cycle 47, Day 1 | -81.76 ± 28.490 |
| Cycle 53, Day 1 | -76.27 ± 34.561 |
| Cycle 59, Day 1 | -64.42 ± 37.677 |
| Cycle 65, Day 1 | -47.58 ± 47.893 |
Assessment of liver volume was performed using serial imaging with magnetic resonance imaging (MRI). Response was defined as resolution of palpable hepatomegaly (CR). Each cycle is 28 days long.
| Percent Change | Avapritinib |
|---|---|
| Cycle 3, Day 1 | -12.45 ± 10.103 |
| Cycle 7, Day 1 | -18.53 ± 12.376 |
| Cycle 11, Day 1 | -22.07 ± 11.603 |
| Cycle 17, Day 1 | -27.92 ± 11.949 |
| Cycle 23, Day 1 | -29.50 ± 12.983 |
| Cycle 29, Day 1 | -29.84 ± 13.588 |
| Cycle 35, Day 1 | -29.81 ± 16.764 |
| Cycle 41, Day 1 | -31.77 ± 16.694 |
| Cycle 47, Day 1 | -34.31 ± 13.973 |
| Cycle 53, Day 1 | -35.86 ± 14.147 |
| Cycle 59, Day 1 | -31.74 ± 18.020 |
| Cycle 65, Day 1 | -26.88 ± 21.594 |
Assessment of spleen volume was performed using serial imaging with MRI. Response was defined as ≥35% reduction in spleen volume (PR) or resolution of palpable splenomegaly (CR). Each cycle is 28 days long.
| Percent Change | Avapritinib |
|---|---|
| Cycle 3, Day 1 | -28.47 ± 26.817 |
| Cycle 7, Day 1 | -35.77 ± 26.770 |
| Cycle 11, Day 1 | -38.71 ± 28.700 |
| Cycle 17, Day 1 | -47.53 ± 23.957 |
| Cycle 23, Day 1 | -44.89 ± 24.377 |
| Cycle 29, Day 1 | -44.30 ± 32.952 |
| Cycle 35, Day 1 | -45.00 ± 32.274 |
| Cycle 41, Day 1 | -51.33 ± 25.812 |
| Cycle 47, Day 1 | -52.45 ± 24.580 |
| Cycle 53, Day 1 | -42.85 ± 45.498 |
| Cycle 59, Day 1 | -40.35 ± 28.396 |
| Cycle 65, Day 1 | -40.27 ± 11.884 |
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Eight symptoms are scored on a scale of 0 to 10 for severity and 2 symptoms (vomiting and diarrhea) are scored for number of episodes. The skin domain is scored on a scale of 0-30, where 0 represents an absence of symptoms and 30 the most severe symptom experience. Similarly, the gastrointestinal domain is scored on a scale of 0-40, where 0 represents an absence of symptoms and 40 the most severe symptom experience. Skin and gastrointestinal domain scores were generated based on average scores for each 7-day period. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
| Score on a Scale | Avapritinib |
|---|---|
| Skin Domain | -2.52 ± 5.362 |
| Gastrointestinal Domain | -2.81 ± 5.172 |
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Eight symptoms are scored on a scale of 0 to 10 for severity. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
| Score on a Scale | Avapritinib |
|---|---|
| Fatigue | -1.12 ± 2.836 |
| Spots | -0.80 ± 2.099 |
| Itching | -0.94 ± 2.302 |
| Flushing | -0.78 ± 2.351 |
| Abdominal Pain | -1.51 ± 2.439 |
| Nausea | -0.75 ± 1.723 |
| Vomiting | -0.03 ± 1.004 |
| Diarrhea | -0.53 ± 1.970 |
The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Two symptoms (vomiting and diarrhea) are scored for number of episodes. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.
| Number of Episodes | Avapritinib |
|---|---|
| Vomiting | 0.31 ± 2.642 |
| Diarrhea | -0.30 ± 2.302 |
The PGIS is a single-item scale that assesses a participant's perception of disease symptoms at a point in time. Scores range from 0 to 4 points, with higher values representing worse symptom outcomes. It is widely used to evaluate a participant's overall sense of whether a treatment has been beneficial. Each cycle is 28 days long.
| Score on a Scale | Avapritinib |
|---|---|
| Cycle 1, Day 15 | -0.7 ± 1.23 |
| Cycle 2, Day 1 | -0.9 ± 1.24 |
| Cycle 3, Day 1 | -1.0 ± 1.20 |
| Cycle 5, Day 1 | -1.0 ± 1.32 |
| Cycle 7, Day 1 | -1.1 ± 1.46 |
| Cycle 9, Day 1 | -1.3 ± 1.50 |
| Cycle 11, Day 1 | -1.3 ± 1.36 |
| Cycle 14, Day 1 | -1.4 ± 1.65 |
| Cycle 17, Day 1 | -1.5 ± 1.41 |
Quality of life was assessed using EORTC QLQ-C30, which is a 30-item questionnaire that includes 5 functional domains (physical, cognitive, role, emotional, and social) and a global health status scale. Twenty-eight questions are scored from 1 (not at all) to 4 (very much), while the other 2 are scored from 1 (very poor) to 7 (excellent). The calculated average is standardized using a linear transformation to a standardized scale of 0 to 100, with a decrease in score representing a decrease in quality of life. Each cycle is 28 days long.
| Score on a Scale | Avapritinib |
|---|---|
| Cycle 1, Day 15 | 14.66 ± 23.397 |
| Cycle 2, Day 1 | 14.33 ± 24.855 |
| Cycle 3, Day 1 | 15.00 ± 28.516 |
| Cycle 5, Day 1 | 14.04 ± 30.042 |
| Cycle 7, Day 1 | 15.85 ± 30.575 |
| Cycle 9, Day 1 | 17.95 ± 29.801 |
| Cycle 11, Day 1 | 18.78 ± 28.179 |
| Cycle 14, Day 1 | 22.32 ± 31.346 |
| Cycle 17, Day 1 | 21.49 ± 29.207 |
A TEAE was defined as any adverse events that occurred between the first dose of a study drug through 30 days after the last dose of any study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Avapritinib |
|---|---|
| Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE) | 107 |
Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).
| ng/mL | Avapritinib |
|---|---|
| Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib | 191 (191 to 191) |
The change in baseline for AdvSM-SAF TSS was correlated with the change in baseline for serum tryptase. Spearman correlation coefficients were performed with corresponding scatter plots on change from baseline.
| Spearman Coefficient | Avapritinib |
|---|---|
| Correlation Between TSS and Serum Tryptase | 0.1043 |
Collected over Day 1 through Month 65. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avapritinib (100 mg) | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| Avapritinib (200 mg) | 33/105 (31.4%) | 67/105 (63.8%) | 104/105 (99%) |
| Event | Avapritinib (100 mg) | Avapritinib (200 mg) |
|---|---|---|
| Cardiac failureCardiac disorders | 1/2 | 3/105 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/2 | 3/105 |
| AscitesGastrointestinal disorders | 1/2 | 1/105 |
| Lymphangiectasia intestinalGastrointestinal disorders | 1/2 | 0/105 |
| Herpes zosterInfections and infestations | 1/2 | 0/105 |
| LymphangiectasiaVascular disorders | 1/2 | 0/105 |
| COVID-19Infections and infestations | 0/2 | 4/105 |
| PneumoniaInfections and infestations | 0/2 | 4/105 |
| Cognitive disorderNervous system disorders | 0/2 | 4/105 |
| NephrolithiasisRenal and urinary disorders | 0/2 | 4/105 |
| Event | Avapritinib (100 mg) | Avapritinib (200 mg) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/2 | 54/105 |
| DiarrhoeaGastrointestinal disorders | 2/2 | 36/105 |
| FatigueGeneral disorders | 2/2 | 22/105 |
| Night sweatsSkin and subcutaneous tissue disorders | 2/2 | 6/105 |
| NeutropeniaBlood and lymphatic system disorders | 1/2 | 24/105 |
| LeukopeniaBlood and lymphatic system disorders | 1/2 | 8/105 |
| Periorbital oedemaEye disorders | 1/2 | 45/105 |
| VomitingGastrointestinal disorders | 1/2 | 24/105 |
| AscitesGastrointestinal disorders | 1/2 | 6/105 |
| Abdominal pain upperGastrointestinal disorders | 1/2 | 5/105 |
Safety Population: all participants who received at least 1 dose of avapritinib.
| Age, Continuous(Years) | Avapritinib |
|---|---|
| Mean | 67.1 ± 10.38 |
| Sex: Female, Male(Participants) | Avapritinib |
|---|---|
| Female | 45 |
| Male | 62 |
| Ethnicity (NIH/OMB)(Participants) | Avapritinib |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 91 |
| Unknown or Not Reported | 14 |
| Race (NIH/OMB)(Participants) | Avapritinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 91 |
| More than one race | 0 |
| Unknown or Not Reported | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Dec 2024, 72 months.
Results were first posted in Apr 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avapritinib
Blueprint Medicines Corporation →